Publications

Resistance to Oral Antibiotics among Urinary Tract Infection Isolates of Escherichia coli from the United States and Europe in 2017. Lead author: IA Critchley, presented at ID Week 2019, October 2-6, Washington, DC, USA
Poster #1465

In Vitro Activity of Lefamulin Against Bacterial Pathogens Causing Community-Acquired Bacterial Pneumonia: SENTRY Surveillance 2017-2018 Results from the United States. Lead author: S Paukner, presented at ID Week 2019, October 2-6, Washington, DC, USA
Poster # 703

Pharmacokinetic-Pharmacodynamic Target Attainment Analyses to Support Lefamulin Dose Justification and Susceptibility Breakpoint Determinations for Patients With Community-Acquired Bacterial Pneumonia. Lead author: SM Bhavnani, presented at ASM/ESCMID 2019, September 3-6, Boston, MA, USA
Poster #19

Lefamulin Activity against Gram-Positive Pathogens Collected in the 2017 Global SENTRY Antimicrobial Surveillance Program. Lead author: S Paukner, presented at ASM/ESCMID 2019, September 3-6, Boston, MA, USA
Poster # T-74

In Vitro Activity of the β-lactamase Inhibitor QPX7728 In Combination with Several β-lactams against Acinetobacter baumannii (AB) and Pseudomonas aeruginosa (PSA). Lead author: M Castanheira, presented at ID Week 2019, October 2-6, Washington, DC, USA
Poster #681

Antimicrobial Activity of the Novel β-Lactam Enhancer Combination Cefepime-Zidebactam (WCK 5222) Tested against Gram-Negative Bacteria Isolated in United States Medical Centers from Patients with Bloodstream Infections. Lead author: M Castanheira, presented at ID Week 2019, October 2-6, Washington DC, USA
Poster #1598

Comparison of cefepime-zidebactam (WCK 5222), ceftazidime-avibactam, and ceftolozane-tazobactam tested against Gram-negative organisms causing pneumonia in United States hospitals in 2018. Lead author: HS Sader, presented at ID Week 2019, October 2-6, Washington, DC, USA
Poster #2214

Frequency and Antimicrobial Susceptibility of Bacteria Isolated from Patients Hospitalized with Pneumonia in US Medical Centers During 2018. Lead Author: HS Sader, presented at ID Week 2019, October 2-6, Washington, DC, USA
Poster #2217

Comparative Antimicrobial Susceptibility of Gram-Negative Bacteria Isolated from Patients with Bloodstream Infections and Pneumonia When Tested against Tazobactam Combinations. Lead author: CG Carvalhaes, presented at ID Week 2019, October 2-6, Washington, DC, USA
Poster #2192

Activity of a Long-Acting Echinocandin, Rezafungin, and Comparator Antifungal Agents Tested against Contemporary Invasive Fungal Isolates: SENTRY 2018. Lead author: MA Pfaller, presented at ID Week 2019, October 2-6, Washington, DC, USA
Poster # 2115

Ceftolozane-Tazobactam Activity against Difficult-to-Treat Resistance in Pseudomonas aeruginosa from Bloodstream Infections in US Hospitals. Lead author: D Shortridge, presented at ID Week 2019, October 2-6, Washington, DC, USA
Poster #1589

Minocycline Activity against Stenotrophomonas maltophilia Isolated from Patients in US Hospitals. Lead author: D Shortridge, presented at ID Week 2019, October 2-6, Washington, DC, USA
Poster #1584

Comparison of Ceftazidime-Avibactam, Ceftolozane-Tazobactam, Piperacillin-Tazobactam, and Meropenem Activities when Tested against Gram-Negative Organisms Isolated from Complicated Urinary Tract Infections. Lead author: HS Sader, presented at ID Week 2019, October 2-6, Washington, DC, USA
Poster # 1436

Eight Years of Sustained Potency and Activity of Oritavancin against Gram-Positive Isolates Causing Bacteremia and Endocarditis in the USA, Including Enterococcal Infections Requiring an Optimized Dosing Strategy for Daptomycin. Lead author: CG Carvalhaes, presented at ID Week 2019, October 2-6, Washington DC, USA
Poster #1583

Antimicrobial Activity of Novel β-Lactamase Inhibitor Combinations Tested against Organisms Causing Complicated Urinary Tract Infections in United States Medical Centers. Lead author: HS Sader, presented at ID Week 2019, October 2-6, Washington, DC, USA
Poster #1445

Delafloxacin Activity against Drug-Resistant Streptococcus pneumoniae, Haemophilus influenzae, Haemophilus parainfluenzae, and Moraxella catarrhalis from US Medical Centers (2014-2018). Lead author: D Shortridge, presented at ID Week 2019, October 2-6, Washington, DC, USA
Poster #1582

Activity of a Novel Polymyxin Analog, QPX9003, Tested against Resistant Gram-Negative Pathogens, Including Carbapenem-Resistant Acinetobacter, Enterobacterales, and Pseudomonas. Lead author: M Castanheira, presented at ID Week 2019, October 2-6, Washington, DC, USA
Poster #690

Antimicrobial Activity of Ceftazidime-Avibactam and Comparator Agents Tested against Gram-Negative Organisms Isolated from Patients with Bloodstream Infections in United States Medical Centers (2017-2018). Lead author: CG Carvalhaes, presented at ID Week 2019, October 2-6, Washington, D. C., USA
Poster #129

Comparison of MIC Results for Gepotidacin by Agar Dilution and Broth Microdilution Methods. Lead author: SJ Ryan Arends, presented at ID Week 2019, October 2-6, Washington, DC, USA
Poster #701

β-Lactam Resistance Mechanisms in Pseudomonas aeruginosa Isolates Analyzed Using Whole Genome Sequencing (WGS) and Transcriptome Analysis and Their Impact in Resistance to New β-Lactam/β-Lactamase Inhibitors. Lead author: M Castanheira, presented at ID Week 2019, October 2-6, Washington DC, USA
Poster #600

Epidemiologic Analysis of a Worldwide Collection of Escherichia coli ST131 Using the 1928D Core Genome Multilocus Sequence Typing Reveals Country Specific and Globally Disseminated Clades. Lead author: LM Deshpande, presented at ID Week 2019, October 2-6, Washington DC, USA
Poster #239

In vitro Activity of Omadacycline against Recent (2018) Bacterial Pathogens Obtained from the United States and Europe from Skin and Skin Structure, Respiratory, and Urinary Tract Infections. Lead author: MD Huband, presented at ID Week 2019, October 2-6, Washington, DC, USA
Poster #665

Activity of Novel β-Lactamase Inhibitor QPX7728 Combined with β-Lactam Agents When Tested against Carbapenem-Resistant Enterobacterales (CRE) Isolates. Lead author: M Castanheira, presented at ID Week 2019, October 2-6, Washington, DC, USA
Poster #677

Ceftobiprole Activity against Pathogens Causing Bacterial Skin and Skin Structure Infections in the United States from 2016 through 2018. Lead author: LR Duncan, presented at ASM/ESCMID 2019, September 3-6, Boston, MA, USA
Poster# T-67

Cefepime-Zidebactam (WCK 5222) Activity against Clinical Isolates of Non-Fermentative Gram-Negative Bacilli Collected Worldwide in 2018. Lead author: HS Sader, presented at ASM/ESCMID 2019, September 3-6, Boston, MA, USA
Poster 69

Antimicrobial Activity of Cefepime-Zidebactam (WCK 5222) against Clinical Isolates of Carbapenem-Resistant Enterobacterales Collected Worldwide in 2018. Lead author: HS Sader, presented at ASM/ESCMID 2019, September 3-6, Boston, MA, USA
Poster 70

In vitro Activity of the Orally Bioavailable Ceftibuten/VNRX-7145 Combination against a Challenge Set of Enterobacteriaceae Pathogens Carrying Molecluarly Characterized β-Lactamase Genes. Lead author: RE Mendes, presented at ASM/ESCMID 2019, September 3-6, Boston, MA, USA
Poster #73

In Vitro Activity of KHP-3757 and Comparators against Recent and Molecularly Characterized Pseudomonas aeruginosa Isolates from a Global Surveillance Program. Lead author: MD Huband, presented at ASM/ESCMID 2019, September 3-6, Boston, MA, USA
Poster

Omadacycline Is Not a Substrate for Clinically Relevant β-Lactamase Enzymes. Lead author: RE Mendes, presented at ASM/ESCMID 2019, September 3-6, Boston, MA, USA
Poster # W-62

Activity of KBP-7072 against Recent and Molecularly Characterized Acinetobacter baumannii Isolates. Lead author: MD Huband, presented at ASM/ESCMID 2019, September 3-6, Boston, MA, USA
Poster # W-69

Regional analysis of telavancin and comparator antimicrobial activity against multidrug-resistant Staphylococcus aureus collected in the United States from 2014 through 2016. by Duncan LR, Smith CJ, Flamm RK and Mendes RE. published in J. Glob. Antimicrob. Resist.: in press, 2019.

Frequency of occurrence and antimicrobial susceptibility of bacteria isolated from patients hospitalized with bloodstream infections in United States medical centers (2015-2017). by Sader HS, Castanheira M, Streit JM and Flamm RK. published in Diag. Microbio. Infect. Dis.: in press, 2019.

The microbiology of bloodstream infection: 20-year trends from the SENTRY Antimicrobial Surveillance Program. by Diekema DJ, Hsueh PR, Mendes RE, Pfaller MA, Rolston KV, Sader HS and Jones RN. published in Antimicrob. Agents Chemother. 2019; 63 (7): e00355

Evaluation of the synergy of ceftazidime-avibactam in combination with meropenem, amikacin, aztreonam, colistin and fosfomycin against well characterized multi-drug resistant K. pneumoniae and P. aeruginosa. by Mikhail S, Singh NB, Kebriaei R, Rice SA, Stamper KC, Castanheira M and Rybak MJ. Antimicrob. Agents Chemother. 2019; 63 (8): e00779

Determination of MIC quality control ranges for the novel gyrase inhibitor, zoliflodacin. by Miller A, Traczewski T, Huband M, Bradford P and Mueller J. published in J. Clin. Microbiol, 2019 57 (9): e00567

Combination of MexAB-OprM overexpression and mutations in efflux regulators, PBPs and chaperone proteins is responsible for ceftazidime/avibactam resistance in Pseudomonas aeruginosa clinical isolates from US hospitals. by Castanheira M, Doyle TB, Smith CJ, Mendes RE and Sader HS. published in J. Antimicrob. Chemother. 2019; 74 (9): 2588-2595

Ceftibuten-Avibactam Activity against β-Lactam-Resistant Enterobacteriaceae Clinical Isolates. Lead author LR Duncan, presented at ASM Microbe 2019, June 20-24, San Francisco, CA, USA
# Sunday-AAR-717

Antimicrobial Activity of Ceftibuten-Clavulanate When Tested against Clinical Enterobacterales Isolates Collected Worldwide in 2017. Lead author: HS Sader, presented at ASM Microbe 2019, June 20-24, San Francisco, CA, USA
# Sunday-AAR-718

Antimicrobial Activity of Plazomicin Tested against a Worldwide Collection of Enterobacterales Isolated from Patients with Complicated Urinary Tract Infections (2014-2017). Lead author: HS Sader, presented at ASM Microbe 2019, June 20-24, San Francisco, CA, USA
# Sunday-AAR-591

Correlation between Broth Microdilution and Disk Diffusion Results When Testing Ceftazidime-Avibactam against a Challenge Collection of Enterobacterales: Results from a Multi-Laboratory Study. Lead author: HS Sader, presented at ASM Microbe 2019, June 20-24, San Francisco, CA, USA
# Sunday-CPHM-866

Plazomicin is Active against Enterobacteriaceae Isolates Producing Extended-Spectrum β-Lactamases, Carbapenemases, and Aminoglycoside-Modifying Enzymes from United States (US) Hospitals. Lead author: M Castanheira, presented at ASM Microbe 2019, June 20-24, San Francisco, CA, USA
# Sunday-AAR-596

Cefepime-Zidebactam (WCK 5222) Activity against Clinical Isolates of Non-Fermentative Gram-Negative Bacilli Collected Worldwide in 2018. Lead author: HS Sader, presented at ASM Microbe 2019, June 20-24, San Francisco, CA, USA
# Sunday-AAR-730

Antimicrobial Activity of High-Dose Extended-Infusion Cefepime-Tazobactam (WCK 4282) Tested against Gram-Negative Organisms Collected from Medical Centers in the United States and Latin America (2018). Lead author: HS Sader, presented at ASM Microbe 2019, June 20-24, San Francisco, CA, USA
# Sunday-AAR-599

Activity of Meropenem-Vaborbactam and Characterization of Carbapenem Resistance Mechanisms among Carbapenem-Resistant Enterobacteriaceae from United States Hospitals (2016-2017). Lead author: M Castanheira, presented at ASM Microbe 2019, June 20-24, San Francisco, CA, USA
# Sunday-AAR-594

Ceftibuten-Clavulanate Activity against Extended-Spectrum β-Lactamase-Producing Escherichia coli and Klebsiella pneumoniae. Lead author: HS Sader, presented at ASM Microbe 2019, June 20-24, San Francisco, CA, USA
# Saturday-AAR-780

Cefepime-Zidebactam (WCK 5222) Activity when Tested against Enterobacterales Isolated from Patients Hospitalized in the United States and Latin America in 2018. Lead author: HS Sader, presented at ASM Microbe 2019, June 20-24, San Francisco, CA
# Saturday-AAR-754

In Vitro Activity of Tedizolid and Comparator Agents against Gram-Positive Isolates Causing Bloodstream Infections in US and European Hospitals (2018). Lead Author: C Carvalhaes, presented at ASM Microbe 2019, June 20-24, San Francisco, CA, USA
#Saturday-AAR-612

Evaluation of Tebipenem Activity Tested against a Collection of Isogenic Escherichia coli Strains Producing Various Clinically Relevant β-Lactamases. Lead author: LM Deshpande, presented at ASM Microbe 2019, June 20-24, San Francisco, CA, USA
# Saturday-AAR-778

Tedizolid In Vitro Activity against a Collection of Multidrug-Resistant Gram-Positive Clinical Isolates from US Medical Centers (2017-2018). Lead author: C Carvalhaes, presented at ASM Microbe 2019, June 20-24, San Francisco, CA, USA
# Saturday-AAR-611

Monitoring the In Vitro Activity of Tebipenem, an Orally Available Carbapenem Agent, against a Current Collection of Surveillance Enterobacterales Clinical Isolates (2018). Lead author: RE Mendes, presented at ASM Microbe 2019, June 20-24, San Francisco, CA, USA
#Saturday-AAR-777